Please assess the completion status of the following clinical trial:

Trial Title: Pemetrexed and Cisplatin as Treatment in Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologic or cytologic diagnosis of Small Cell Lung Cancer (SCLC).~* Functional stage from 0 to 2 of the ECOG functional scale~* No previous systemic chemotherapy, immunotherapy or biologic therapy for SCLC.~* Previous bone marrow radiotherapy less than 25% is allowed.~* There must be at least one measurable lesion that complies with the solid tumor response evaluation criteria.~* Appropriate organic function.~* Life expectancy estimated at 12 weeks minimum.~* Females must be surgically sterile, postmenopausal or follow approved medical contraceptive methods during the treatment period and 6 months afterwards. Males must be surgically sterile or use a contraceptive method during the treatment period and during 6 months after treatment.~* The patient must be compliant and located close to the trial area for appropriate follow-up.~* The patient or his/her legal representative must sign an informed consent document.~* Patients must be at least 18 years of age.~Exclusion Criteria:~* Having received treatment for the last 30 days with a drug that has not obtained regulatory approval.~* Having participated in a previous pemetrexed trial.~* Mixed histologic diagnosis of SCLC and NSCLC.~* Concurrent illness.~* Having an active infection.~* Severe cardiac disease.~* Having received recently or concurrently a vaccine against yellow fever.~* Having suffered a previous malignant process other than SCLC.~* Central nervous system (CNS) metastases require concurrent corticoid therapy. Treated and stable CNS metastases are allowed.~* Clinically relevant fluid accumulation in the third space.~* Significant weight loss (greater than or equal to 10%) within 6 weeks prior to trial inclusion.~* Concurrent administration of any other anti-tumor treatment.~* Severe renal failure.~* Unable to discontinue administration of non-steroidal anti-inflammatory (NSAIDS) agents.~* Inability or unwillingness to take folic acid and vitamin B12 supplements.~* Inability to take corticoids.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).